
Regeneron Pharmaceuticals Inc
XBER:RGO

Intrinsic Value
The intrinsic value of one
RGO
stock under the Base Case scenario is
156.82
EUR.
Compared to the current market price of 128.94 EUR,
Regeneron Pharmaceuticals Inc
is
Undervalued by 18%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Regeneron Pharmaceuticals Inc
Loading...
Fundamental Analysis

Regeneron’s overreliance on Eylea for a significant portion of its revenue poses a major risk, especially as new anti-VEGF therapies and biosimilars could challenge its market share in retinal diseases and pressure pricing.
Despite Eylea’s looming patent expiry, potential label expansions for Dupixent and newer pipeline candidates like pozelimab could diversify revenue sources and provide steady earnings growth.

Revenue & Expenses Breakdown
Regeneron Pharmaceuticals Inc
Balance Sheet Decomposition
Regeneron Pharmaceuticals Inc
Current Assets | 17.6B |
Cash & Short-Term Investments | 8.3B |
Receivables | 5.6B |
Other Current Assets | 3.7B |
Non-Current Assets | 20B |
Long-Term Investments | 9.3B |
PP&E | 4.7B |
Intangibles | 1.2B |
Other Non-Current Assets | 4.8B |
Free Cash Flow Analysis
Regeneron Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Regeneron Pharmaceuticals Inc
Revenue
|
14.1B
USD
|
Cost of Revenue
|
-1.9B
USD
|
Gross Profit
|
12.2B
USD
|
Operating Expenses
|
-8.1B
USD
|
Operating Income
|
4.1B
USD
|
Other Expenses
|
435.8m
USD
|
Net Income
|
4.5B
USD
|
RGO Profitability Score
Profitability Due Diligence
Regeneron Pharmaceuticals Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Score
Regeneron Pharmaceuticals Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
RGO Solvency Score
Solvency Due Diligence
Regeneron Pharmaceuticals Inc's solvency score is 97/100. The higher the solvency score, the more solvent the company is.

Score
Regeneron Pharmaceuticals Inc's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RGO Price Targets Summary
Regeneron Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
RGO
is 645.69 EUR
with a low forecast of 438.09 EUR and a high forecast of 915.4 EUR.
Dividends
Current shareholder yield for REGN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
RGO
stock under the Base Case scenario is
156.82
EUR.
Compared to the current market price of 128.94 EUR,
Regeneron Pharmaceuticals Inc
is
Undervalued by 18%.